CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2023

Dec 13, 2023

Appendix 3Y Change of Director’s Interest Notice

3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Phillip Hains
Date of Last Notice:	17 July 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest	Indirect
Nature of indirect interest	Director related entity
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Date of change	7		December 2023
No. of securities held prior to change				Shares		Options
			Direct	-		-
			Indirect	6,754,599		142,860
			Total	6,754,599		142,860
Class	Fully Paid Ordinary Shares
Number acquired				Shares		Options
			Direct	-		-
			Indirect	3,571,429		-
			Total	3,571,429		-
Number disposed				Shares		Options
			Direct	-		-
			Indirect	-		-
			Total	-		-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration		$0.028 per share	$0.028 per share
Note:
If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change			Shares		Options
		Direct		-	-
		Indirect	10,326,028		142,860
		Total	10,326,028		142,860
Nature of change	Issue of securities via Entitlement Offer
Example:	announced 25 October			2023.
on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation
in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide
details and an estimated valuation
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

1/01/2011